



Incidence of Dysplasia in Patients with Barrett's Esophagus

Thesis

*Submitted for Partial Fulfillment of
Master Degree In General Surgery*

Presented by

Karim Wahid Shawky

MB.B.CH, Faculty of Medicine, Ain Shams University

Supervised by

Prof.Dr.Hisham Abd EL Raouf El Akkad

Professor of General Surgery

Faculty of Medicine, Ain Shams University

Dr. Amr Mohammed Mahmoud El Hefny

Associate Professor of General Surgery

Faculty of Medicine, Ain Shams University

Dr. Mohammed Abd Almegeed Al Sayed

Lecturer of General Surgery

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ

فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم
سورة النساء آية (١١٣)

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Hisham Abd El Raouf El Akkad**, Professor of General Surgery Faculty of Medicine, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Amr Mohammed Mahmoud El Hefny**, Associate Professor of General Surgery Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Mohammed Abd Almegeed Al Sayed**, Lecturer of General Surgery Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

Karim Wahid Shawky

List of Contents

Title	Page No.
List of Abbreviations	5
List of Tables	7
List of Figures	8
Introduction	1
Aim of this Study	3
Review of Literature	
▪ Historical evolution of the diagnostic criteria for Barrett's esophagus	4
▪ Histo-Pathology of Barrett's Esophagus	7
▪ Risk factors in Barrett's Esophagus	18
▪ Diagnosis of Barret's Esophagus	26
▪ Management of Barrett's Esophagus	32
Patients and Methods	47
Results	50
Discussion	61
Summary	65
Conclusion	67
References	68
Arabic Summary	

List of Abbreviations

Abb.	Full term
95% CI	95% Confidence interval
AGA	American Gastro-enterological Association
APC.....	Argon Plasma Coagulation
B.....	Regression coefficients
BE	Barrett's esophagus
BMI.....	Body Mass Index
BOBCAT	Benign Barrett's and Cancer Taskforce
BSG.....	British Society of Gastroenterology
C & M	Circumferential extent and the Maximum extent
CLE.....	Confocal Laser Endomicroscopy
COX-2	Cyclooxygenase-2
DM	Diabetes mellitus
EMR.....	Endoscopic Mucosal Resection
EUS.....	Endoscopic Ultrasonography
GERD.....	Gastro-esophageal reflux disease
GOJ.....	Gastro-esophageal junction
HGD.....	High grade dysplasia
IM.....	Intestinal Metaplasia
LGD	Low grade dysplasia
LNF.....	Laparoscopic Nissen Fundoplication
NF	Nissen Fundoplication
NSAIDs.....	Non steroidal anti-inflammatory drugs
NSE.....	Neo-squamous Epithelium
OCT.....	Optical Coherence Tomography
OR	Odds Ratio
OR.....	Odds ratio
pCLE.....	Probe-based system Confocal Laser Endomicroscopy

List of Abbreviations Cont...

Abb.	Full term
PDT.....	Photodynamic Therapy
PGE-2	Prostaglandin E-2
PPI	Proton pump inhibitor
P-value.....	Probability value
RFA.....	Radiofrequency Ablation
S.E.....	Standard error of regression coefficients
SCJ.....	Squamo-columnar Junction
TFF3	Trefoil Factor-3
TNE	Trans-nasal Endoscopy
VLE.....	Volumetric Laser Endomicroscopy
Wald.....	Statistical test
WLE.....	White Light Endoscopy

List of Tables

Table No.	Title	Page No.
Table (1):	Comparison between BSG guidelines, AGA guidelines and BOBCAT consensus in the diagnosis of Barrett's esophagus.....	9
Table (2):	Guidelines for management of patients with BE without dysplasia.....	45
Table (3):	Guidelines for management of patients with BE with dysplasia.....	46
Table (4):	Showing percentage of each risk factor present in relation to the total patient number.	50
Table (5):	Showing the incidence of dysplasia in relation to gender and age.	53
Table (6):	Showing the incidence of dysplasia in relation to smoking, obesity (BMI > 35) and DM.	55
Table (7):	Showing the incidence of dysplasia in relation to reflux duration and medical treatment received as PPIs.....	56
Table (8):	Showing the incidence of dysplasia in relation to esophagitis.....	58
Table (9):	Showing the incidence of dysplasia in relation to presence of hiatus hernia.....	59
Table (10):	Logistic regression analysis for predictors of dysplasia.	60

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Norman Barrett	4
Fig. (2):	Normal distal esophagus and examples of Barrett's esophagus.	6
Fig. (3):	Intestinal metaplasia in esophageal columnar epithelium	11
Fig. (4):	The Prague classification showing the circumferential (C) and maximum (M) extent.....	12
Fig. (5):	Progressive sequence in Barrett's esophagus	14
Fig. (6):	Spectrum of dysplasia in Barrett's esophagus.....	17
Fig. (7):	Chromoendoscopy using Lugol's iodine in the esophagus.....	28
Fig. (8):	Comparison between pCLE images and histopathological images.....	29
Fig. (9):	Volumetric Laser Endomicroscopy	29
Fig. (10):	Tethered-capsule Endomicroscopy	30
Fig. (11):	The Cytosponge expanded (left) and encapsulated (right).....	31
Fig. (12):	Nissen fundoplication.....	34
Fig. (13):	Esophagectomy operation.....	36
Fig. (14):	Endoscopic mucosal resection (EMR) for early esophageal adenocarcinoma	40
Fig. (15):	Radiofrequency ablation (RFA) of Barrett's esophagus	42
Fig. (16):	A 71-year-old male with long-segment Barrett's esophagus	43
Fig. (17):	Argon plasma coagulation of residual Barrett's mucosa.....	44
Fig. (18):	Pie chart showing the gender of the candidate patients.....	51

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (19):	Column chart showing percentage of smokers, obese (BMI > 35) and diabetic patients in the study.	51
Fig. (20):	Pie chart showing percentage of patients who received a medical treatment for reflux.	52
Fig. (21):	Column chart showing percentage of esophagitis, hiatus hernia and dysplasia among the patients.	52
Fig. (22):	Column chart showing percentage of patients developed dysplasia in relation to gender.	53
Fig. (23):	Column chart showing the mean age for developing dysplasia.	54
Fig. (24):	Column chart showing percentage of patients developed dysplasia in relation to smoking, obesity and DM.	55
Fig. (25):	Column chart showing the mean reflux duration to develop dysplasia.	56
Fig. (26):	Column chart showing percentage of patients developed dysplasia in relation to receiving reflux treatment.	57
Fig. (27):	Column chart showing percentage of patients developed dysplasia in relation to esophagitis.	58
Fig. (28):	Column chart showing percentage of patients developed dysplasia in relation to presence of hiatus hernia.	59

INTRODUCTION

Barrett's esophagus is a condition which predisposes towards development of esophageal adenocarcinoma, a highly lethal tumour which has been increasing in incidence over the past three decades. There have been tremendous advances in the field of Barrett's esophagus, not only in diagnostic modalities, but also in therapeutic strategies available to treat this premalignant disease (*Tan et al., 2017*).

Barrett's esophagus patients progress through a phenotypic sequence of no dysplasia, low-grade dysplasia, high-grade dysplasia and then into esophageal adenocarcinoma, although the time course is highly variable. Furthermore, some patients may progress directly to cancer without prior detection of dysplasia of any grade. Currently, dysplasia remains the only practical factor useful for identifying patients at increased risk for the development of esophageal adenocarcinoma in clinical practice (*Gaddam et al., 2013*).

A number of endoscopic, histologic and epidemiologic risk factors identify Barrett's esophagus patients at increased risk for progression to high-grade dysplasia and esophageal adenocarcinoma. Endoscopic factors include segment length, mucosal abnormalities as esophagitis and the 12 to 6 o'clock hemisphere of the esophagus. Epidemiologic risk factors include

aging, male gender, obesity, and smoking. Factors that may protect against the development of adenocarcinoma include a diet rich in fruits and vegetables, and the use of proton pump inhibitors, aspirin/NSAIDs and statins (*Falk, 2015*).

AIM OF THIS STUDY

The aim of this study is to evaluate the incidence of dysplasia in patients with Barrett's esophagus in relation to risk factors such as: gender, smoking, obesity, patient's age, duration of reflux, treatment received, associated disease as DM and esophageal histopathology.

Chapter 1

HISTORICAL EVOLUTION OF THE DIAGNOSTIC CRITERIA FOR BARRETT'S ESOPHAGUS

Barrett's esophagus gets its name from the pioneering British surgeon, Norman Barrett who in 1950 published his paper 'Chronic peptic ulcer of the esophagus and esophagitis' where he described the columnar lined esophagus. Over the next four decades, disagreements regarding the distal esophageal histology were prevalent, with some arguing that the ulcers in the distal esophagus were not esophageal, but gastric ulcers within an intra-thoracic stomach in patients with congenital short esophagus (*Barrett, 1950*).



Fig. (1): Norman Barrett (<https://www.readersdigest.co.uk/health/health-conditions/all-you-need-to-know-about-barretts-oesophagus>).

In 1953, Allison and Johnstone published an influential report rejecting Barrett's hypothesis, and suggesting that the

tubular structure within the distal thorax could not be stomach since it: 1) lacked an outer peritoneal lining; 2) had musculature identical to esophagus; 3) consisted of columnar epithelium interspersed with squamous islands; 4) lacked mucosal oxyntic cells; and 5) had mucosal glands typical of the esophagus (*Allison and Johnstone, 1953*).

Subsequent re-assessment of these gastric ulcers by Barrett led him to acknowledge his prior misjudgement, and he published a revised report in 1957, redefining this tubular structure as 'Lower esophagus lined by columnar epithelium' (*Barrett, 1957*).

Between 1960 to the mid-1970s, there were varying histological descriptions of the columnar subtypes in the distal esophagus including junctional (gastric cardiac epithelium), gastric-fundal, and intestinal epithelium with goblet cells (*Hayward, 1961*).

In the 1980s it was established that chronic gastro-esophageal reflux disease and the presence of a hiatal hernia were risk factors for Barrett's esophagus and it grew to be appreciated that these could distort the anatomic landmarks of the GOJ during endoscopy making a precise diagnosis difficult. To avoid error, diagnostic criteria for Barrett's esophagus were established that a minimum of 3 cm columnar lining is required to diagnose Barrett's esophagus and for enrolment into clinical studies. By the mid-1980s, the association between Barrett's

esophagus and esophageal adenocarcinoma was well established and it became clear that intestinal metaplasia had a mosaic distribution with strong predisposition to dysplasia which led to intestinal metaplasia becoming the defining feature for Barrett's esophagus (*Hamilton and Smith, 1987*).

In the mid-1990s, Spechler challenged the conventional practice of only performing biopsies on Barrett's esophagus ≥ 3 cm because he demonstrated that 18% of patients with endoscopically apparent Barrett's esophagus measuring less than 3 cm still contained intestinal metaplasia. These results, coupled with the categorization of Barrett's esophagus into short (≤ 3 cm) and long segments (≥ 3 cm) have proved essential in shaping the diagnostic criteria for Barrett's esophagus over the years (*Spechler et al., 1994*).




Fig. (2): Normal distal esophagus and examples of Barrett's esophagus. (<http://www.gastromedicine.com.au/barretts-oesophagus/>).